Annual Meeting

Stressed out? The cancer playbook may help

Learn about the session on stress adaptations in tumor progression in the Maximizing Access Committee’s symposium at Discover BMB 2024
Jonathan A. Kelber
By Jonathan A. Kelber
Sept. 14, 2023

We often associate the concept of stress with deadlines, emergencies, traffic or hardships. For those who study biological and biochemical processes of disease in cell and organismal models, the idea of stress adaptation is recognized as one mechanism by which malignant and nonmalignant cells survive and thrive within environments that, at times, are hostile.

Are there ways that we think about environmental stress adaptations at an organismal level that may help scientists develop new perspectives on combatting cancer to improve patient outcomes? Indeed, cancer cells may even engage in molecular decision-making activities that differentiate between fight-or-flight responses in the face of environmental stress.

Submit an abstract

Abstract submission begins Sept. 14. If you submit by Oct. 12, you'll get a decision by Nov. 1. The regular submission deadline is Nov. 30. See the categories.

This session will consider the mechanisms by which cancer cells adapt to intrinsic and extrinsic stressors and how defining these adaptative mechanisms may lead to improved treatment strategies. Topics will include nutrient access/use, aging, subcellular compartments, microenvironmental influences and tissue reprogramming.

Keywords: Cancer biology, molecular crosstalk, biochemical signaling, tissue homeostasis, aging, subcellular transport, local and global adaptations, tumor microenvironment.

Who should attend: Cancer researchers, cell biologists and biochemists interested in considering how aging, biochemistry and multi-scale adaptations cooperate to shape the stress landscapes of tumors.

Theme song: “Stressed Out” by A Tribe Called Quest

This session is powered by cortisol and catecholamines.

Stress adaptations in tumor progression

Jonathan Kelber (chair), Baylor University

Elda GrabockaThomas Jefferson University

Christina TowersSalk Institute for Biological Studies

Mark LaBargeBeckman Research Institute of City of Hope

 

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Jonathan A. Kelber
Jonathan A. Kelber

Jonathan A. Kelber is an associate professor of biology at Baylor University.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

The quest to treat and cure xerostomia
Interview

The quest to treat and cure xerostomia

July 23, 2024

Blake Warner, chief of the Salivary Disorders Unit at the NIH talks about his lab’s efforts to develop treatments for dry mouth.

There's more to blue cheese than just the stench
News

There's more to blue cheese than just the stench

July 21, 2024

Virginia Tech researchers discovered a way to synthesize a compound in the mold of blue cheese that has antibacterial and anticancer properties.

Engineering cells to broadcast their behavior can help scientists study their inner workings
News

Engineering cells to broadcast their behavior can help scientists study their inner workings

July 20, 2024

Researchers can use waves to transmit signals from the invisible processes and dynamics underlying how cells make decisions.

From the journals: JBC
Journal News

From the journals: JBC

July 19, 2024

Lung cancer cells resist ferroptosis. ORMDL3 in ulcerative colitis. Novel genetic variants in thyroid cancer. Read about these recent papers.

Seeking the sweet spot to beat a pig parasite
Journal News

Seeking the sweet spot to beat a pig parasite

July 16, 2024

Researchers extracted, separated and tested glycans from the porcine whipworm in an effort to determine the best way to develop treatments and vaccines.

Radioactive drugs strike cancer with precision
News

Radioactive drugs strike cancer with precision

July 14, 2024

The tumor-seeking radiopharmaceuticals are charting a new course in oncology, with promise for targeted treatments with fewer side effects.